Trial reportProstate cancer and prostatic diseases2011
Symptomatic and urodynamic responses in patients with reduced or no seminal emission during silodosin treatment for LUTS and BPH.
Trial report in Prostate cancer and prostatic diseases, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Multi-Center, Randomized, Double-Blind, Placebo Controlled, Parallel Evaluation of the Efficacy and Safety of a New Drug in the Treatment of the Signs and Symptoms of Benign Prostatic Hyperplasia
A Multi-Center, Randomized, Double-Blind, Placebo Controlled, Parallel Evaluation of the Efficacy and Safety of a New Drug in the Treatment of the Signs and Symptoms of Benign Prostatic Hyperplasia
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 60 citations in OpenAlex.
- Systematic review and meta-analysis of randomized controlled trials evaluating silodosin in the treatment of non-neurogenic male lower urinary tract symptoms suggestive of benign prostatic enlargement.World journal of urology · 2013Pooled it
- Open-label, 9-month extension study investigating the uro-selective alpha-blocker silodosin in men with LUTS associated with BPH.World journal of urology · 2015Trial
- Risks and side effects in the medical management of benign prostatic hyperplasia.Prostate international · 2024Review
- Current and emerging treatment options for premature ejaculation.Nature reviews. Urology · 2022Review
- Evolving Role of Silodosin for the Treatment of Urological Disorders - A Narrative Review.Drug design, development and therapy · 2022Review
- Comparative Efficacy of Different Drugs for Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia: A Bayesian Network Meta-Analysis.Frontiers in pharmacology · 2022Review
- Focus on Silodosin: Pros and Cons of Uroselectivity.Research and reports in urology · 2020Review
- Silodosin Has Nocebo Effect on Sexual Adverse Effects: A Randomized Controlled Trial.The Eurasian journal of medicine · 2019Article
- Premature ejaculation: challenging new and the old concepts.F1000Research · 2017Review
- Emerging and investigational drugs for premature ejaculation.Translational andrology and urology · 2016Review
- The role of orgasm in the development and shaping of partner preferences.Socioaffective neuroscience & psychology · 2016Article
- Advances in understanding and treating premature ejaculation.Nature reviews. Urology · 2015Review
- Latest developments in the assessment and treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: what is clinically relevant?Clinical drug investigation · 2015Article
- Silodosin: a review of its use in the treatment of the signs and symptoms of benign prostatic hyperplasia.Drugs · 2015Review
- Silodosin for the treatment of clinical benign prostatic hyperplasia: safety, efficacy, and patient acceptability.Research and reports in urology · 2014Review
- Investigation of ejaculatory disorder by silodosin in the treatment of prostatic hyperplasia.BMC urology · 2012Article
- Review
- Safety and efficacy of silodosin for the treatment of benign prostatic hyperplasia.Clinical interventions in aging · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Data from phase 3 studies (NCT00224107, NCT00224120) of silodosin for treatment of BPH symptoms were analyzed to examine the relationship between treatment efficacy and occurrence of abnormal ejaculation. Men aged ≥50 years with International Prostate Symptom Scores (IPSS) ≥13 and peak urinary flow rates (Qmax) of 4-15 ml s(-1) received placebo or silodosin 8 mg once daily for 12 weeks. Silodosin-treated patients were stratified by absence or presence of 'retrograde ejaculation' (RE). Groups were compared using analysis of covariance (for change from baseline) and responder analyses. Of the 466 patients receiving silodosin, 131 (28%) reported RE and 335 (72%) did not; 4 of the 457 patients receiving placebo (0.9%) reported RE. Most RE events in silodosin-treated patients (110/134; 82%) were reported as 'orgasm with absence of seminal emission.' Silodosin-treated patients with (+) and without (-) RE showed significant improvement in IPSS, Qmax and quality of life versus placebo (P<0.02). RE+ patients versus RE- patients experienced numerically greater improvement, but differences were not statistically significant (P>0.05). For RE+ patients, the odds of achieving improvement of ≥3 points in IPSS and ≥3 ml s(-1) in Qmax by study end were 1.75 times those for RE- patients (P=0.0127). Absence of seminal emission may predict superior treatment efficacy of silodosin in individual patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.